Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor

(2016) Yong Jia et al.   CANCER RESEARCH

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

(2016) Yoshiko Urata et al.   JOURNAL OF CLINICAL ONCOLOGY

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

(2016) Barbara Klughammer et al.   Journal of Thoracic Oncology

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis

(2016) Li-Yang Chen et al.   LUNG CANCER

Update to Rociletinib Data with the RECIST Confirmed Response Rate

(2016) Lecia V. Sequist et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers

(2016) Boram Lee et al.   Oncotarget

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

(2015) Jarushka Naidoo et al.   CANCER

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

(2015) M. J. Niederst et al.   CLINICAL CANCER RESEARCH

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

(2015) Y. Kobayashi et al.   CLINICAL CANCER RESEARCH

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy inEGFR-Mutant Lung Cancer: A Meta-Analysis

(2015) Chee Khoon Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

(2015) Chao-Hua Chiu et al.   Journal of Thoracic Oncology

EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey

(2015) Yasushi Yatabe et al.   Journal of Thoracic Oncology

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

(2015) James C-H Yang et al.   LANCET ONCOLOGY

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

(2015) Lecia V. Sequist et al.   NEW ENGLAND JOURNAL OF MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

(2015) D. F. Heigener et al.   ONCOLOGIST

EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis

(2015) Chao Cheng et al.   Scientific Reports

Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma

(2014) Yunjian Pan et al.   ANNALS OF SURGICAL ONCOLOGY

Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors

(2014) Hyun Sun Woo et al.   INVESTIGATIONAL NEW DRUGS

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients

(2014) Jangchul Park et al.   Journal of Thoracic Oncology

Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort

(2014) Helena A. Yu et al.   Journal of Thoracic Oncology

Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment

(2014) Aglaya G. Iyevleva et al.   Journal of Thoracic Oncology

Clinical and in vivo Evidence that EGFR S768I Mutant Lung Adenocarcinomas Are Sensitive to Erlotinib

(2014) Matthew D. Hellmann et al.   Journal of Thoracic Oncology

Rare EGFR Exon 20 S768I Mutation Predicts Resistance to Targeted Therapy: A Report of Two Cases

(2014) Lalit Pallan et al.   Journal of Thoracic Oncology

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q

(2014) Satoshi Watanabe et al.   Journal of Thoracic Oncology

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

(2014) Yuankai Shi et al.   Journal of Thoracic Oncology

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

(2014) Pasi A Jänne et al.   LANCET ONCOLOGY

Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer

(2014) Toshihiko Kaneda et al.   LUNG CANCER

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

(2013) M. Beau-Faller et al.   ANNALS OF ONCOLOGY

Power in Numbers: Meta-analysis to Identify Inhibitor-Sensitive Tumor Genotypes

(2013) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

An Uncommon Insertion Mutation in Exon 19 of EGFR Showed Stable Disease after TKI Treatment

(2013) Anthony W.H. Chan et al.   Journal of Thoracic Oncology

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

(2013) Neal I. Lindeman et al.   Journal of Thoracic Oncology

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer

(2013) Victor H.F. Lee et al.   Journal of Thoracic Oncology

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

(2013) Geoffrey R. Oxnard et al.   Journal of Thoracic Oncology

EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter

(2013) Pei Jye Voon et al.   MOLECULAR CANCER THERAPEUTICS

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

(2013) M. E. Arcila et al.   MOLECULAR CANCER THERAPEUTICS

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

(2013) H. Yasuda et al.   Science Translational Medicine

Clinical Outcomes in Non-Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR

(2012) K.-P. Chung et al.   CLINICAL CANCER RESEARCH

Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

(2012) Geoffrey R. Oxnard et al.   Journal of Thoracic Oncology

Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations

(2012) Marius Lund-Iversen et al.   Journal of Thoracic Oncology

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

(2012) Susumu Kobayashi et al.   Journal of Thoracic Oncology

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

KIF5B-RET fusions in lung adenocarcinoma

(2012) Takashi Kohno et al.   NATURE MEDICINE

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

(2011) M. He et al.   CLINICAL CANCER RESEARCH

Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer

(2011) J.-Y. Wu et al.   CLINICAL CANCER RESEARCH

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing

(2011) Y. S. Ju et al.   GENOME RESEARCH

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

(2011) Hiroyuki Yasuda et al.   LANCET ONCOLOGY

Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I)

(2010) K. Masago et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids

(2008) Z Chen et al.   ONCOGENE

Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR) Mutations with the Classical Mutation Pattern

(2008) S.-G. Wu et al.   ONCOLOGIST